NEW YORK CITY — For decades, the landscape of cardiovascular medicine has been defined by technological triumphs, most notably the transition of aortic stenosis (AS) from a high-mortality condition to one manageable through sophisticated, minimally invasive procedures. Yet, even as clinical excellence in the operating room reaches an all-time high, a new national quality registry study suggests that the "upstream" journey—the path from initial detection to definitive treatment—remains fraught with systemic inefficiencies.
Presented at the New York Valves annual meeting and simultaneously published in the journal Circulation, the American Heart Association’s "Target: Aortic Stenosis" (Target: AS) registry offers a sobering, yet optimistic, look at how the U.S. healthcare system handles one of the most common and serious valvular heart diseases. While the data shows marked improvements in diagnostic speed, a significant "treatment gap" persists, leaving nearly one in six eligible patients waiting too long for life-saving interventions.
Main Facts: The State of Aortic Stenosis Care
The Target: AS registry, which draws data from 58 participating clinical sites across the United States, provides the first national, granular look at the quality of care for patients suffering from AS. The analysis focused on 8,097 patients with a median age of 76.5 years, nearly half of whom were women.
The findings highlight a two-tier reality in modern cardiology:
- Diagnostic Gains: The proportion of patients who received all confirmatory diagnostic assessments within 30 days of an initial echocardiogram showing moderate or severe AS rose to 61.4% in 2024, up from 54.2% in 2023. This statistically significant improvement suggests that awareness campaigns and better clinical workflows are beginning to bear fruit.
- The Treatment Stagnation: Conversely, among patients with a Class I indication for aortic valve replacement (AVR)—the gold standard for symptomatic severe AS—the rate of timely treatment (defined as intervention within 90 days) remained effectively flat. In 2024, 84.7% of these patients received timely treatment, compared to 82.2% in 2023.
While an 84.7% success rate may appear high, Dr. Brian Lindman of Vanderbilt University Medical Center, the study’s lead investigator, emphasized the human cost of the remaining 15.3%. "Nearly one in six eligible individuals did not get AVR within the 90-day window," Lindman noted. In a condition where delay is synonymous with increased mortality and diminished quality of life, these numbers represent a critical failure in the continuum of care.
Chronology of a Medical Transformation
To understand the current state of AS care, one must look at the historical trajectory of the field. Two decades ago, a diagnosis of severe symptomatic aortic stenosis was often a harbinger of a poor prognosis, with 1-year mortality rates hovering around 50%. The advent of Transcatheter Aortic Valve Replacement (TAVR) fundamentally altered this calculus.
- The Pre-TAVR Era: Characterized by limited options for elderly, high-risk patients who were often deemed "inoperable" due to the invasiveness of open-heart surgery.
- The TAVR Revolution: Over the last 15 years, TAVR moved from a niche, experimental procedure for the most fragile patients to a standard of care for low-risk populations. Today, 1-year mortality rates for patients undergoing these procedures have plummeted to approximately 1–2%.
- The Current Registry Era: As procedural outcomes have stabilized at an elite level, the medical community has shifted its focus to the "upstream" process. The Target: AS registry marks the beginning of a new phase, where the goal is no longer just procedural success, but excellence in the entire patient journey—from the moment a murmur is heard to the completion of the valve replacement.
Supporting Data: Why Delays Persist
The registry study reveals that the barriers to timely treatment are not merely bureaucratic, but deeply clinical. The data identified several specific "process of care" failures that contribute to the 90-day delay:
- Incomplete Diagnostics: A significant number of patients fail to receive necessary secondary testing, such as stroke volume index reporting or advanced multimodality imaging, which are essential to confirming the precise severity of the stenosis.
- Symptom Assessment Gaps: The registry highlighted a lack of consistent, standardized symptom assessment. Because AVR is indicated based on the presence of symptoms, a failure to accurately document these symptoms—such as exertional shortness of breath or lightheadedness—effectively keeps a patient trapped in the "moderate" category, even when they are physiologically ready for surgery.
- The "Volume" Paradox: As TAVR has become more accessible, hospital systems have struggled to keep pace with the sheer volume of referrals. High demand has led to longer wait times, a phenomenon that has been previously linked to an overall uptick in AS-related deaths. The registry confirms that even in well-resourced sites, the logistics of scheduling and patient throughput remain a significant hurdle.
Official Responses and Expert Perspective
The release of the registry report coincided with a period of intense scrutiny regarding federal oversight of heart valve care. The Centers for Medicare & Medicaid Services (CMS) recently released a proposed national coverage determination for TAVR, signaling a potential expansion of the procedure’s accessibility. While many in the cardiology community welcome this expansion, experts warn that increasing access to the procedure without addressing the upstream bottlenecks could exacerbate existing wait-time issues.
Dr. Dharam Kumbhani, of UT Southwestern Medical Center, noted that the registry is an essential tool for identifying where the system breaks down. "The Target AS registry represents an important advance in moving beyond procedural excellence towards excellence across the entire continuum of care," Kumbhani stated. He stressed that the one-in-six delay rate is unacceptable given that we now possess the tools to cure the condition.
Dr. Roxana Mehran, of the Mount Sinai Health System, provided a more targeted critique, highlighting the potential for disparities. "We must be deeply concerned about access and timely treatment in vulnerable patient populations and women," Mehran argued. The registry data, which shows that 47% of the cohort were women, serves as a prompt for clinicians to ensure that gender-based differences in symptom presentation do not lead to missed or delayed diagnoses.
Implications for the Future of Cardiology
The Target: AS registry is not merely a static report; it is the foundation of a broader, more ambitious undertaking: the Heart Valve Initiative. Dr. Lindman confirmed that plans are already underway to expand the registry from 58 sites to 200, with an ultimate goal of incorporating data on other valve pathologies, including mitral and tricuspid regurgitation.
The Path Forward
For hospitals and healthcare systems, the implications are clear:
- Workflow Optimization: Clinical sites must move toward "AS Heart Teams" that integrate primary care, cardiology, and imaging specialists to ensure that diagnostic data flows seamlessly and that symptomatic patients are identified early.
- Standardization of Metrics: The registry highlights that what gets measured gets managed. By adopting the metrics used in the Target: AS registry, hospitals can self-audit their wait times and identify the specific points of failure—whether it be in the imaging department or the valve clinic—that keep patients from reaching the operating room in a timely fashion.
- Policy and Regulation: As CMS moves forward with its proposed coverage changes, the data from the Heart Valve Initiative will likely play a role in shaping how centers are incentivized to maintain quality. The shift toward value-based care suggests that future reimbursement may be tied not just to the success of the valve replacement itself, but to the efficiency with which a patient is navigated through the health system.
Ultimately, the registry serves as a reminder that in the era of high-tech cardiology, the most profound improvements in patient outcomes may not come from a new device or a more precise catheter, but from the simple, disciplined execution of care processes. As the medical community looks toward the next decade of heart valve treatment, the focus must remain on the patient who is still waiting—ensuring that their path to recovery is as swift as the technology that will eventually save them.
